[CLSTR]
< Back to situations

[ORGANIZATION]

Medicines and Healthcare products Regulatory Agency

Featured in 24 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

291 clusters · 1104 sources · last updated

Latest: Novo Nordisk faces lawsuits over Ozempic and NAION risks

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr

[ACTIVE] [HEALTH] [GB] [IN]

Global healthcare and AI hardware regulatory developments

5 clusters · 23 sources · last updated

Latest: United Kingdom to implement continuous monitoring for AI medical devices

Regulatory authorities in India and the United Kingdom are advancing distinct frameworks to address the integration of artificial intelligence into healthcare, pharmaceuticals, and critical hardware sectors. In India, t

[QUIET] [BUSINESS] [GB] [US] [DE]

uniQure Huntington’s disease gene therapy regulatory filings

3 clusters · 9 sources · last updated

Latest: uniQure releases mixed 48-month clinical data for AMT-130

uniQure has initiated regulatory approval processes for AMT-130, a gene therapy designed to treat the underlying cause of Huntington’s disease. The company submitted a Biologics License Application to the U.S. Food and D

[QUIET] [HEALTH] [US] [GB]

Global peptide research and regulatory developments

2 clusters · 12 sources · last updated

Latest: Peptide research advances in formulation and discovery

Peptides are experiencing increased interest across medical, wellness, and skincare sectors, driven by scientific research into longevity and the popularity of GLP-1 medications. In the United States, an FDA advisory com

[QUIET] [HEALTH] [GB] [AU] [HR]

Global safety concerns regarding GLP-1 weight loss drugs

2 clusters · 11 sources · last updated

Latest: Weight loss drugs linked to serious side effects and vision loss

Health authorities are monitoring a surge in reported adverse reactions and deaths linked to GLP-1 receptor agonists used for weight loss and diabetes, including semaglutide, tirzepatide, and liraglutide. Initial report

[QUIET] [HEALTH] [US]

Trump administration reforms childhood vaccine schedule

11 clusters · 364 sources · last updated

Latest: Trump announces plan to split childhood vaccines into five doses

In August 2026, the Trump administration overhauled the federal childhood vaccination schedule through an executive order titled ‘Delivering Gold Standard Childhood Vaccine Recommendations For Americans.’ Supported by He

[QUIET] [HEALTH] [US] [GB]

US opioid overdose death rate declines

5 clusters · 16 sources · last updated

Latest: Naloxone distribution linked to declining overdose deaths in Alabama and Connecticut

Various regions in the United States are reporting declines in opioid-related deaths, attributed to expanded harm reduction efforts and training. In New Bedford, Massachusetts, fatal overdoses decreased from 84 in 2022 t

Also covered in